Micromet Inc.
NASDAQ:MITI ISIN:US59509C1053
Micromet, Inc. (NASDAQ:MITI) is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based therapies for the treatment of cancer. The Company’s product development pipeline includes antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. As of December 31, 2009, five of its antibodies are in clinical trials, while the remainder of its product pipeline is in preclinical development. Micromet’s lead product candidate is the BiTE antibody blinatumomab, also known as MT103. Blinatumomab targets the human protein molecule CD19, which is expressed on the surface of tumor cells of certain cancers. Micromet is also evaluating blinatumomab in an ongoing phase I clinical trial for the treatment of patients with non-Hodgkin’s lymphoma (NHL). Its second clinical-stage BiTE antibody MT110, is in a phase I clinical trial for the treatment of patients with solid tumors.
News
Micromet Inc. (OJ:MITI) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
Micromet Inc. (OJ:MITI) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
Micromet Inc. (OJ:MITI) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
Micromet Inc. (OJ:MITI) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
Micromet Inc. (OJ:MITI) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
###
2,028 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 4) (Last 30 Days: 14) (Since Published: 2028)
